Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

People who are eligible can book their Covid-19 and flu jabs from today, as health leaders urge the public to get vaccinated ...

October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.

The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...

A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...

Those eligible for Covid and flu jabs have been urged to start getting vaccinated as soon as possible to be protected.

Bookings for vaccines are open now on the NHS website or by calling 119. Flu jabs will be given from October 3 to those 65 ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV viruses that cause a significant burden of disease in elderly patients and those ...